Tonix Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 65 to 78.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or better RS Rating in the early stages of their moves. See if Tonix Pharmaceuticals can continue to rebound and clear that threshold.
While now is not an ideal time to invest, see if the stock is able to form a base and break out.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at -10%.
The company earns the No. 263 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
